Anavex Life Sciences Corp.
AVXL
$4.20
-$0.06-1.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.13M | 3.68M | 4.50M | 2.62M | 3.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.75M | 10.83M | 14.33M | 12.42M | 13.18M |
| Operating Income | -6.75M | -10.83M | -14.33M | -12.42M | -13.18M |
| Income Before Tax | -5.66M | -9.83M | -13.24M | -11.20M | -12.11M |
| Income Tax Expenses | 18.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.68M | -9.83M | -13.24M | -11.20M | -12.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.68M | -9.83M | -13.24M | -11.20M | -12.11M |
| EBIT | -6.75M | -10.83M | -14.33M | -12.42M | -13.18M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.06 | -0.11 | -0.16 | -0.13 | -0.14 |
| Normalized Basic EPS | -0.04 | -0.07 | -0.10 | -0.08 | -0.09 |
| EPS Diluted | -0.06 | -0.11 | -0.16 | -0.13 | -0.14 |
| Normalized Diluted EPS | -0.04 | -0.07 | -0.10 | -0.08 | -0.09 |
| Average Basic Shares Outstanding | 89.03M | 85.89M | 85.38M | 85.07M | 84.81M |
| Average Diluted Shares Outstanding | 89.03M | 85.89M | 85.38M | 85.07M | 84.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |